Title

An update on diagnosis and therapeutics for type-2 diabetes mellitus

Authors

Shyamaladevi Babu*¹, Ipsita Dash², Ramya Badrachalam³, Madhan Krishnan¹, Arjunkumar Panneerselvam⁴ & Sadhana Undru⁵

Affiliation

¹Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India; ²Department of biochemistry, Saheed Laxman Nayak Medical College and Hospital, Pujariput, Koraput, Odisha- 764020; ³Department of Biochemistry, Sri Manakula Vinayagar Medical College & Hospital, Madagadipet, Kalitheerthalkuppam, Puducherry – 605107, Puducherry, India; ⁴Department of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, Tamil Nadu, India; ⁵Department of Mental Health Nursing, Kims college of Nursing, KIMS & RF, Amalapuram, East Godavari district, Andhra Pradesh, India; *Corresponding author

Email

Shyamaladevi Babu - E-mail: shyamdevi06@gmail.com; dr.shyamaladevi@care.edu.in 

Ipsita Dash - E-mail: ipsitadash71@gmail.com

Ramya Badrachalam - E-mail: drramya830@gmail.com

Madhan Krishnan - E-mail: kmadhan91@gmail.com; drmadhan@care.edu.in

Arjunkumar Panneerselvam - E-mail: arjunkumarpharm@gmail.com

Sadhana Undru – E-mail: sadhanaundru@gmail.com

Article Type

Research Article

Date

Received March 1, 2023; Revised March 31, 2023; Accepted March 31, 2023, Published March 31, 2023

Type-2 Diabetes mellitus is a common metabolic disorder. It is combined with co-morbidities, such as obesity, hyperlipidemia, hypertension and cardiovascular disease which taken together, comprise the ‘Metabolic Syndrome’. This disease causes crucial morbidity and mortality at considerable expense to patients, their families and society. Different categories of drugs such as insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, GLP-1 agonists, DPP4 inhibitors, dual PPAR agonists and others are used for its management. Therefore, it is of interest to highlight the recent advances in diagnosis and therapeutics used in the treatment of type-2 diabetes mellitus. The classical and online-literature were used to compile data for this study. This includes the electronic search engine such as Scopus, Google Scholar, Sci Finder, PubMed and Web of Science. Data shows that there are different families of oral and injectable drugs at hand for the treatment of T2DM. Hence, we need to develop a novel, safety and effective agents that will improve the quality of life of T2DM patients, considering effectiveness and durability of lowering blood Glucose, risk of hypoglycemia and diabetes complications.

Keywords

Type 2 diabetes mellitus; Diagnosis; Oral drugs; Insulin Secretagogues; Insulin sensitizer and dipeptidyl peptidase-4 inhibitors

Citation

     Babu et al. Bioinformation 19(3): 295-298 (2023)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.